Prolonged Half-life of Voriconazole in a CYP2C19 Homozygous Poor Metabolizer Receiving Vincristine Chemotherapy: Avoiding a Serious Adverse Drug Interaction

We report a case of prolonged half-life of voriconazole due to CYP2C19*2/*2 poor metabolizer genotype in a patient receiving vincristine chemotherapy. Voriconazole was discontinued three days before start of vincristine to avoid a serious drug interaction. Therapeutic drug monitoring and genotyping...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Moriyama, Brad, Falade, Oluwaseun, Leung, Janice, Penzak, Scott R., JJingo, Caroline, Huang, Xuan, Henning, Stacey A., Wilson, Wyndham H., Walsh, Thomas J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3164277/
https://ncbi.nlm.nih.gov/pubmed/21615537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1439-0507.2011.02016.x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller